Limb Ischemia disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LMB062 MIFTS: 54	Limb Ischemia Categories: Cardiovascular diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Limb Ischemia

MalaCards integrated aliases for Limb Ischemia:

Name: Limb Ischemia ¹¹ ¹⁴ ³⁶ ⁷¹

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:0050852

UMLS ⁷¹ C2945695

Sources

Summaries for Limb Ischemia

Disease Ontology: ¹¹ An ischemia that is characterized by low blood supply to tissues in the limb due to interruption in the arterial blood supply.

MalaCards based summary: Limb Ischemia is related to intermittent claudication and temporal arteritis. An important gene associated with Limb Ischemia is MIR126 (MicroRNA 126), and among its related pathways/superpathways are ERK Signaling and Signal Transduction. The drugs Acetylsalicylic acid and Evolocumab have been mentioned in the context of this disorder. Affiliated tissues include Limb and Bone, and related phenotypes are nervous system and homeostasis/metabolism

Sources

Related Diseases for Limb Ischemia

Diseases related to Limb Ischemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 775)

#	Related Disease	Score	Top Affiliating Genes
1	intermittent claudication	32.0	VWF VEGFA TEK IL6 CRP
2	temporal arteritis	31.9	VWF VEGFA IL6 CRP
3	ischemia	31.4	VEGFA TEK NOS3 MIR21 MIR17 MIR126
4	peripheral vascular disease	31.4	VWF VEGFA NOS3 MIR126 KDR IL6
5	compartment syndrome	31.3	IL6 F3 CRP
6	peripheral artery disease	31.3	VWF VEGFA PECAM1 NOS3 MIR21 MIR17
7	arteriosclerosis obliterans	31.3	MIR21 MIR126 IL6 HGF
8	buerger disease	31.2	VEGFA NOS3 HGF FGF2 CRP CD34
9	aortic dissection	31.2	NOS3 IL6 HIF1A CRP
10	congestive heart failure	31.1	VWF VEGFA IL6 ANGPT1
11	adult respiratory distress syndrome	31.0	MIR21 MIR126 IL6 CRP ANGPT1
12	cerebrovascular disease	31.0	MIR21 MIR17 MIR126 IL6 CRP
13	covid-19	30.9	NOS3 IL6 F3 CRP
14	arteries, anomalies of	30.9	VEGFA NOS3 MIR21 MIR17 MIR126 MIR10A
15	aortic aneurysm	30.9	VEGFA NOS3 MIR21 MIR126 IL6 F3
16	chronic kidney disease	30.8	VWF NOS3 MIR21 MIR126 IL6 HGF
17	systemic scleroderma	30.7	VEGFA MIR21 IL6 CRP CD34
18	aortic aneurysm, familial abdominal, 1	30.7	VEGFA PECAM1 NOS3 MIR21 MIR126 IL6
19	lipid metabolism disorder	30.7	NOS3 MIR21 MIR17 MIR126 IL6 CRP
20	collagen disease	30.6	VWF IL6 CRP
21	polyarteritis nodosa	30.6	PECAM1 IL6 CRP
22	toxic shock syndrome	30.6	IL6 F3 CRP
23	pulmonary embolism	30.6	VWF MIR126 F3 CRP
24	heart septal defect	30.6	MIR17 F3 CRP
25	antiphospholipid syndrome	30.6	VWF F3 CRP
26	atherosclerosis susceptibility	30.6	VWF NOS3 IL6 F3 CRP
27	patent foramen ovale	30.6	VWF IL6 F3 CRP
28	arteriosclerosis	30.5	PECAM1 MIR21 MIR126 IL6 HIF1A HGF
29	essential thrombocythemia	30.5	VWF IL6 FGF2 CD34
30	severe covid-19	30.5	VWF MIR21 IL6 F3 CRP
31	pulmonary edema	30.5	TEK NOS3 HIF1A HGF CRP
32	urinary tract infection	30.5	IL6 F3 CRP
33	microvascular complications of diabetes 1	30.5	VEGFA HIF1A HGF FGF2 CXCL12 ANGPT1
34	vascular disease	30.5	VWF VEGFA TEK NOS3 MIR21 MIR126
35	respiratory failure	30.4	VWF VEGFA MIR21 MIR17 MIR126 IL6
36	transient cerebral ischemia	30.4	VWF IL6 F3 CRP
37	disseminated intravascular coagulation	30.4	VWF IL6 F3 CRP
38	thrombocytosis	30.4	VWF IL6 F3 CRP
39	leukostasis	30.4	VEGFA KDR IL6
40	nonbacterial thrombotic endocarditis	30.4	VWF F3 CRP
41	angina pectoris	30.4	NOS3 IL6 F3 CRP
42	chronic ulcer of skin	30.3	VEGFA MIR21 IL6 FGF2 CRP
43	atrial fibrillation	30.3	VWF MIR21 IL6 F3 CRP
44	purpura	30.3	VWF IL6 F3 CRP
45	necrotizing fasciitis	30.3	IL6 F3 CRP
46	hyperglycemia	30.3	NOS3 MIR126 IL6 HIF1A
47	varicose veins	30.3	VWF VEGFA KDR IL6 HIF1A
48	cellulitis	30.3	IL6 F3 CRP
49	aortic valve disease 2	30.3	VWF MIR21 MIR17 MIR126 CRP
50	polycythemia	30.3	VEGFA HIF1A F3 CRP

Graphical network of the top 20 diseases related to Limb Ischemia:

Sources

Symptoms & Phenotypes for Limb Ischemia

MGI Mouse Phenotypes related to Limb Ischemia:

⁴⁵ (show all 14)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	nervous system	MP:0003631	10.31	ANGPT1 CXCL12 ENG F3 FGF2 HGF
2	homeostasis/metabolism	MP:0005376	10.31	ANGPT1 CD34 CRP ENG F3 FGF2
3	cardiovascular system	MP:0005385	10.27	ANGPT1 CRP CXCL12 ENG F3 FGF2
4	muscle	MP:0005369	10.26	ANGPT1 CXCL12 ENG F3 FGF2 HIF1A
5	cellular	MP:0005384	10.22	CD34 CXCL12 F3 FGF2 HGF HIF1A
6	normal	MP:0002873	10.18	CXCL12 ENG F3 HIF1A KDR MIR10A
7	immune system	MP:0005387	10.13	ANGPT1 CD34 CRP CXCL12 ENG F3
8	neoplasm	MP:0002006	10.08	CD34 F3 FGF2 HIF1A IL6 MIR10A
9	liver/biliary system	MP:0005370	10.06	CXCL12 HGF HIF1A IL6 KDR NOS3
10	no phenotypic analysis	MP:0003012	10.05	CXCL12 HGF KDR MIR10A MIR126 VEGFA
11	respiratory system	MP:0005388	9.91	ENG F3 HIF1A IL6 KDR MIR126
12	vision/eye	MP:0005391	9.85	ANGPT1 F3 FGF2 HIF1A IL6 KDR
13	hematopoietic system	MP:0005397	9.83	CD34 CXCL12 ENG F3 FGF2 HGF
14	mortality/aging	MP:0010768	9.5	ANGPT1 CXCL12 ENG F3 FGF2 HGF

Sources

Drugs & Therapeutics for Limb Ischemia

Drugs for Limb Ischemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 168)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Acetylsalicylic acid

Approved, Vet_approved

Phase 4

50-78-2

2244

Evolocumab

Approved

Phase 4

1256937-27-5

Alprostadil

Approved, Investigational

Phase 4

745-65-3

5280723

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 4

1177-87-3

3680

Dexamethasone

Approved, Investigational, Vet_approved

Phase 4

50-02-2

3003 5743

Pregabalin

Approved, Investigational

Phase 4

148553-50-8

5486971

Arginine

Approved, Investigational, Nutraceutical

Phase 4

74-79-3

6322

Anti-Asthmatic Agents

Phase 4

Respiratory System Agents

Phase 4

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Phase 4

Antimetabolites

Phase 4

Hypolipidemic Agents

Phase 4

Anticholesteremic Agents

Phase 4

Lipid Regulating Agents

Phase 4

Fibrinolytic Agents

Phase 4

Antipyretics

Phase 4

Cyclooxygenase Inhibitors

Phase 4

Bronchodilator Agents

Phase 4

Neuroprotective Agents

Phase 4

Phosphodiesterase Inhibitors

Phase 4

Phosphodiesterase 3 Inhibitors

Phase 4

Pharmaceutical Solutions

Phase 4

Vasodilator Agents

Phase 4

Hormone Antagonists

Phase 4

Antineoplastic Agents, Hormonal

Phase 4

Antiemetics

Phase 4

glucocorticoids

Phase 4

Gastrointestinal Agents

Phase 4

Hormones

Phase 4

Analgesics

Phase 4

Calcium, Dietary

Phase 4

Anti-Anxiety Agents

Phase 4

Psychotropic Drugs

Phase 4

Anticonvulsants

Phase 4

calcium channel blockers

Phase 4

Calcium

Nutraceutical

Phase 4

7440-70-2

271

Caffeine

Approved

Phase 3

58-08-2

2519

Apixaban

Approved

Phase 3

503612-47-3

10182969

Edetate calcium disodium anhydrous

Approved, Vet_approved

Phase 3

62-33-9, 60-00-4

6049

Iron

Approved

Phase 3

7439-89-6

29936

Pentetic acid

Approved

Phase 3

67-43-6

Procaine

Approved, Investigational, Vet_approved

Phase 3

59-46-1

4914

Montelukast

Approved

Phase 3

158966-92-8

5281040

Iodine

Approved, Investigational

Phase 3

7553-56-2

807

Sirolimus

Approved, Investigational

Phase 3

53123-88-9

5284616 6436030

Miconazole

Approved, Investigational, Vet_approved

Phase 3

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 3

23593-75-1

2812

Clopidogrel

Approved

Phase 2, Phase 3

120202-66-6, 113665-84-2

60606

Ticagrelor

Approved

Phase 2, Phase 3

274693-27-5

9871419

Treprostinil

Approved, Investigational

Phase 3

81846-19-7

6918140

Interventional clinical trials:

(show top 50) (show all 329)

#	Name	Status	NCT ID	Phase	Drugs
1	Effect of Evolocumab in Patients With Critical Limb Ischemia	Unknown status	NCT04306471	Phase 4	Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months.
2	Efficacy of Alprostadil as an Adjuvant Therapy With Indirect Angiosomal Revascularization in Patients With Critical Limb Ischemia.	Unknown status	NCT04312555	Phase 4	Alprostadil
3	Comparison of Cilostazol-based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy for Outcomes of below-the Knee Endovascular Intervention in Patients With Critical Limb Ischemia (TAP CLI Study)	Unknown status	NCT02829151	Phase 4	Triple antiplatelet therapy (aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) );Dual antiplatelet therapy (aspirin (100 mg) and clopidogrel (75 mg)) using aspirin and clopidogrel;Dual antiplatelet therapy (aspirin (100 mg) and cilostazol (200 mg)) using aspirin and cilostazol
4	Optimized Strategy for Diabetic Patients With Critical Limb Ischemia: A Multi-center, Randomized Controlled Trial and Registration Study(Part I)	Unknown status	NCT01171703	Phase 4
5	DCLI-II:Optimized Strategy for Diabetic Patients With Critical Limb Ischemia: A Multi-center, Randomized Controlled Trial and Registration Study(Part II)	Unknown status	NCT01173094	Phase 4
6	Protective Effects of L-arginine During Reperfusion by Femoropopliteal Bypass for Lower Limb Ischemic Syndrome in Humans	Completed	NCT02117206	Phase 4	L-arginine (L-arginine Veyron);Nacl
7	Physician Initiated Trial Investigating the Efficacy of the Implant of EverFlex 200mm Long Nitinol Stents in TASC C&D Femoropopliteal Lesions	Completed	NCT00637741	Phase 4
8	CLIMB Prospective Multicenter Registry Evaluating the Use of the PolarCath Peripheral Dilatation System (Boston Scientific) in the Treatment of Infrapopliteal Lesions in Patients With Critical Limb Ischemia (Rutherford 4 and 5).	Completed	NCT00459888	Phase 4
9	Physician Initiated Multi-center Belgian-Italian-Dutch Trial Investigating Abbott Vascular Iliac Stents in the Treatment of TASC A, B, C & D Iliac Lesions	Completed	NCT00764777	Phase 4
10	International Postmarketing Surveillance Study of Pl-VEGF165 Safety and Efficacy in 210 Patients With Peripheral Arterial Disease	Completed	NCT02369809	Phase 4	Neovasculgen®
11	EXPAND Study - Self Expanding Nitinol Stent Versus PTA With Optional Bailout Stenting in Case of PTA Failure in Patients With Symptomatic Critical Limb Ischemia or Severe Intermittent Claudication. A Prospective, Multi-center, Randomized Clinical Trail With Follow-up Investigations at 1, 3, 6, and 12 Months.	Completed	NCT00906022	Phase 4
12	Choice of Material for Above-Knee Femoro-Popliteal Bypass Prosthetic Graft. Multicenter Randomized Study of an Impregnated Knitted Polyester Prosthesis Vs. PTFE (Uni-Graft Vs Gore-Tex).	Completed	NCT00300690	Phase 4
13	Randomized Controlled Trial of Paclitaxel Drug-coated Balloons vs. Nitinol Stent for Femoropopliteal Obstructions - The PAVENST Trial	Completed	NCT02212470	Phase 4
14	Drug Eluting Balloon in peripherAl inTErvention For Below The Knee Angioplasty Evaluation: the DEBATE-BTK Study	Completed	NCT01558505	Phase 4
15	Evaluation of the Use of ACOTEC Drug-Eluting Balloon Litos ® in Below-The-Knee Arteries to Treat Critical Limb Ischemia	Completed	NCT02563535	Phase 4
16	Multinational, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel Groups Study to Assess the Efficacy and Safety of Prostaglandin E1 in Subjects With Critical Limb Ischemia (Fontaine Stage IV)	Completed	NCT00596752	Phase 4	Alprostadil
17	Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging	Active, not recruiting	NCT02807779	Phase 4	Dexamethasone infusion
18	Physician-initiated Trial Investigating the MOTIV™ Bioresorbable Scaffold (Reva Medical) for the Treatment of Below-The-Knee Artery Disease	Active, not recruiting	NCT03987061	Phase 4
19	Pregabalin for Pain Reduction in Critical Limb Ischemia - A Double Blind, Randomized Controlled Study	Terminated	NCT00403780	Phase 4	pregabalin;placebo
20	Plaque Removal Versus Open Bypass Surgery For Critical Limb Ischemia	Terminated	NCT00504088	Phase 4
21	Proteomics and Stem Cell Therapy as a New Vascularization Strategy	Withdrawn	NCT02408991	Phase 4	Neupogen
22	Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization	Unknown status	NCT03006770	Phase 3
23	Safety and Effectiveness of the SurgWerksTM-CLI Kit and VXPTM System for the Rapid Intra-operative Aspiration, Preparation and Intramuscular Injection of Concentrated Autologous Bone Marrow Cells Into the Ischemic Index Limb of Rutherford Category 5 Non-Reconstructable Critical Limb Ischemia Patients	Unknown status	NCT02538978	Phase 3
24	An Efficacy and Safety Study to Evaluate Ranger Drug-eluting Balloon for Below the Knee Angioplasty in Patients With Critical Limb Ischemia	Unknown status	NCT02856230	Phase 2, Phase 3
25	Distal Venous Arterialisation in the Treatment of Critical Ischemia of Lower Limb	Unknown status	NCT01211925	Phase 2, Phase 3	Aspirin
26	Autologous Bone Marrow-derived Mononuclear Cells for Therapeutic Arteriogenesis in Patients With Limb Ischemia A Double Blind, Placebo Controlled, Study in Diabetic and Non-diabetic Patients	Unknown status	NCT00539266	Phase 2, Phase 3
27	Study of Parameters of Infracyanine Angiography as Diagnostic Tool of Critical Limb Ischemia	Unknown status	NCT02820467	Phase 3
28	Pilot Study of Treatment of Chronic Critical Limb Ischemia With G-CSF-mobilized Autologous Peripheral Blood Mononuclear Cells	Completed	NCT01833585	Phase 3
29	Monocentric Randomized Study for the Therapy of Critic Limb Ischemia With Bone Marrow- or Peripheral Blood-derived Stem Cells	Completed	NCT02454231	Phase 2, Phase 3
30	Pivotal Study of the Safety and Effectiveness of Autologous Bone Marrow Aspirate Concentrate (BMAC) for the Treatment of Critical Limb Ischemia Due to Peripheral Arterial Disease	Completed	NCT01245335	Phase 3
31	Randomised Clinical Study of Safety and Efficacy of Autologous Bone Marrow Aspirate Concentrate (BMAC) for No-option_critical Limb Ischemia in Type-II Diabetes Mellitus Patients. (DIALEG)	Completed	NCT01818310	Phase 2, Phase 3
32	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Ixmyelocel-T In Subjects With Critical Limb Ischemia And No Options For Revascularization	Completed	NCT01483898	Phase 3
33	Cell Therapy in Critical Limb Ischemia	Completed	NCT00904501	Phase 3
34	A Randomized Double-Blind Placebo-Controlled Parallel Group Study of the Efficacy and Safety of XRP0038/NV1FGF on Amputation or Any Death in Critical Limb Ischemia Patients With Skin Lesions	Completed	NCT00566657	Phase 3
35	Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in Subjects With Symptomatic Peripheral Artery Disease (PAD) Undergoing Infrapopliteal Endovascular Peripheral Revascularization Procedures in Patients With Critical Limb	Recruiting	NCT04229264	Phase 3	Apixaban;ASA;Clopidogrel 75mg
36	Trial to Assess Chelation Therapy in Critical Limb Ischemia	Recruiting	NCT03982693	Phase 3	Edetate Disodium
37	Paclitaxel Eluting Stent in Long Superficial Femoral Artery Obstruction: a Prospective, Randomized Comparison With Bypass Surgery Using PTFE Graft in a Finnish Multicenter Study	Recruiting	NCT01450722	Phase 3
38	A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of NL003 in Subject With Critical Limb Ischemia（Rutherford 5）	Recruiting	NCT04274049	Phase 3
39	A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of NL003 in Subject With Critical Limb Ischemia(Rutherford 4)	Recruiting	NCT04275323	Phase 3
40	Regeneration of Ischemic Damages in Cardiovascular System Using Wharton's Jelly as an Unlimited Source of Mesenchymal Stem Cells for Regenerative Medicine. Project of the National Centre for Research and Development (Poland) 'STRATEGMED II'. Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With No-option Critical Limb Ischemia (N-O CLI)	Active, not recruiting	NCT03423732	Phase 2, Phase 3	CardioCell;Placebos
41	A Randomized Trial Comparing the Drug-Eluting Stent (DES) Below-the-Knee (BTK) Vascular Stent System (DES BTK Vascular Stent System) vs Percutaneous Transluminal Angioplasty (PTA) Treating Infrapopliteal Lesions in Subjects With Critical Limb Ischemia	Active, not recruiting	NCT03551496	Phase 3
42	The Efficacy and Safety of Intra-arterial Administration of REX-001 to Treat Ischemic Ulcers in Subjects With Critical Limb Ischemia (CLI) Rutherford Category 5 and Diabetes Mellitus: A Pivotal, Placebo-controlled, Double-blind, Parallel-group, Adaptive Trial	Active, not recruiting	NCT03174522	Phase 3	REX-001;Placebo
43	Percutaneous Transluminal Balloon Angioplasty (PTA) and Drug Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia	Active, not recruiting	NCT00471289	Phase 2, Phase 3
44	The Assessment of Cysteinyl Leukotriene Receptor Antagonist Role in Inhibition of Atherosclerosis, Proliferation and Its Influence on Endothelial Function in Patients Undergoing Endovascular Treatment Due to Peripheral Arterial Disease.	Not yet recruiting	NCT04277702	Phase 3	Montelukast 10mg;Standard anti-platelet treatment
45	Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Temsirolimus Perivascular Injection 0.1 mg/mL on the Incidence of Ischemia-Driven Major Amputation, Clinically Driven Target Lesion Revascularization, and Clinically Relevant Target Lesion Occlusion After Revascularization of Lesions Below the Knee in Patients With Symptomatic Rutherford 3-5 Peripheral Artery Disease	Not yet recruiting	NCT04433572	Phase 3	Temsirolimus;Saline placebo
46	Multicenter, Open-label, Randomized Clinical Trial of Efficacy and Safety of the Thrombolysis With Recombinant Non-immunogenic Staphylokinase (Fortelyzin®) in Patients With ALI vs Surgery	Not yet recruiting	NCT05372718	Phase 3	Recombinant non-immunogenic staphylokinase (Fortelyzin®)
47	A Phase 3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AMG0001 in Subjects With Critical Limb Ischemia	Terminated	NCT02144610	Phase 3
48	A Randomized Placebo-Controlled, 12-Week Multicenter Study of the Safety and Efficacy of Continuous or Daily Administration of Remodulin® (Treprostinil Sodium) Injection in Patients With CLI With No Planned Revascularization Procedures	Terminated	NCT00060996	Phase 3	Remodulin® (treprostinil sodium) Injection
49	Patients With Diabetic Foot Syndrome and Critical Limb Ischemia - a Randomized Clinical Trial With Urokinase	Terminated	NCT01638585	Phase 3	urokinase
50	The Efficacy and Safety of Intra-arterial Administration of REX-001 to Treat Ischemic Rest Pain in Subjects With Critical Limb Ischemia (CLI) Rutherford Category 4 and Diabetes Mellitus (DM): a Pivotal, Placebo-controlled, Double-blind, Parallel-group, Adaptive Trial	Terminated	NCT03111238	Phase 3	REX-001;Placebo

Search NIH Clinical Center for Limb Ischemia

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about Limb Ischemia cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Limb Ischemia:

	ACP-01, autologous angiogenic precursor cells for critical limb ischemia
	ACT34-CLI, bone marrow-derived cells for critical limb ischemia
	ACY001, bone marrow-derived hematopoietic stem cells for treatment of critical limb ischemia
	ALD-301, bone marrow-derived cells for critical limb ischemia
	Alecmestencel-T, mesenchymal stem cells for ischemic diseases
	ALO212, umbilical cord blood-derived stem cell concentrate for vascular diseases
	Angiocell, bone marrow-derived stem cells for treatment of critical limb ischemia
	Autologous CD133+ cells for treatment of critical limb ischemia
	Autologous endothelial progenitor cells for the treatment of critical limb ischemia
	Autologus endothelial progenitor cells for the treatment of critical limb ischemia
	Autologus hematopoeitic stem cells for the treatment of critical limb ischemia
	BMAC, autologous bone marrow aspirate concentrate for critical limb ischemia
	Bone marrow-derived CD133+ or nucleated cells for peripheral artery disease
	Bone marrow-derived mononuclear cells for critical limb ischemia
	Bone marrow-derived mononuclear cells for peripheral vascular disease
	Bone marrow-derived mononuclear stem cells for treatment of critical limb ischemia
	Bone marrow-derived stem cells for treatment of critical limb ischemia and diabetic foot ulcer
	Bone marrow-derived stem cells for treatment of diabetic foot ulcers
	Enriched bone marrow-derived progenitor cells for ischemic diseases
	ERCs, endometrial regenerative cells for critical limb ischemia
	Hematopoietic stem cells for limb ischemia and diabetic neuropathy
	itMSC, bone marrow-derived mesenchymal stem cells for cardiovascular diseases
	Ixmyelocel-T, mesenchymal stem cells and myocytes for critical limb ischemia
	Mesendo, stem cell combination for treatment of limb ischemia
	MultiGeneAngio, genetically modified endothelial and smooth muscle cells for vascular disease
	PDA002, Placenta-derived cells for vascular disease
	Peripheral blood-derived hematopoietic stem cells for leg gangrene
	PLX-PAD, placental-derived mesenchymal-like stromal cells for peripheral artery disease
	ReN009, human neural stem cells for peripheral arterial disease
	RNL-Astrostem, adipose-derived mesenchymal stem cells for treatment of peripheral vascular diseases
	StempeucelCLI, mesenchymal stem cells for vascular diseases
	Umbilical cord blood stem cells for treatment of critical limb ischemia

Embryonic/Adult Cultured Cells Related to Limb Ischemia:

	Angiogenic cell precursors
	Bone marrow-derived CD34+ stem cells (ACT34) PMIDs: 9020076 23192920 22163120
	Bone marrow-derived ALDH+ cells (ALD) PMIDs: 10430905 19324906
	Bone marrow-derived mesenchymal stem cells (family)
	Cord blood-derived hematopoietic stem cell PMIDs: 19558779
	Bone marrow-derived mononuclear cells (family) PMIDs: 17394441 23586040 21216483
	Peripheral blood-derived endothelial progenitor cells (family)
	Peripheral blood-derived endothelial cells PMIDs: 18388019 19448678
	Peripheral blood-derived hematopoietic stem cells PMIDs: 18388019
	Bone Marrow Aspirate Concentrated Nucleated Cells (BMAC) PMIDs: 15995108 18351022 22019148 19896796 19500466
	Bone marrow-derived mononuclear cells
	Bone marrow-derived mononuclear cells
	Tissue repair cells PMIDs: 17394441 23586040
	Bone marrow-derived mesenchymal stem cells PMIDs: 21216483
	Bone marrow-derived progenitor cells
	Endometrial regenerative cells PMIDs: 18005405 18713449 19232091
	Peripheral blood-derived hematopoietic stem cells (family)
	Bone marrow-derived mesenchymal stem cells and monocytes (Ixmyelocel-T) PMIDs: 22453769 22776246 21684715
	Bone marrow-derived mesenchymal stem cells PMIDs: 21586448
	Bone marrow-derived mononuclear cells PMIDs: 21586448
	MultiGeneAngio, transduced vein-derived endothelial cells
	Genetically modified vein-derived smooth muscle
	MultiGeneAngio, transduced vein-derived smooth muscle cells
	Genetically modified vein-derived endothelial cells
	Placenta-derived cells
	Peripheral blood-derived hematopoietic stem cells
	Placenta-derived adherent stromal cell (PLX) PMIDs: 18154467 19526389 19478280
	Neural stem cell line (CTX0E03) PMIDs: 23067568
	Adipose-derived mesenchymal stem cells PMIDs: 21303266 24341080
	Bone marrow-derived mesenchymal stem cells (Stempeucel) PMIDs: 23307180 18720444 22731756
	Umbilical cord blood-derived hematopoietic stem cells (family)

Sources

Genetic Tests for Limb Ischemia

Sources

Anatomical Context for Limb Ischemia

Organs/tissues related to Limb Ischemia:

MalaCards : Bone Marrow, Bone, Placenta, Endothelial, Smooth Muscle, Skeletal Muscle, Small Intestine

Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Limb Ischemia:

#	Tissue Anatomical CompartmentCell	Relevance
1	Limb Pelvic Girdle Bone Marrow Stromal Cells	Potential therapeutic candidate
2	Bone Bone Marrow Bone Marrow Stromal Cells	Potential therapeutic candidate
3	Placenta Chorionic Villus Chorionic Mesenchymal Stromal Cells	Potential therapeutic candidate
4	Adipose Subcutaneous White Adipose Mesenchymal Stem Cells	Potential therapeutic candidate
5	Adipose Subcutaneous White Adipose Stromal Cells	Potential therapeutic candidate

Sources

Publications for Limb Ischemia

Articles related to Limb Ischemia:

(show top 50) (show all 8740)

#	Title	Authors	PMID	Year
1	Study Protocol of a Prospective Multicenter Observational Study Evaluating Acute Lower Limb Ischemia. ⁶²	Gratl A...European Vascular Research Collaborative (EVRC)	36347128	2023
2	Acute limb ischaemia in a young male with secondary polycythaemia: A case report. ⁶²	Kam CT...Sip B	36452889	2023
3	Free floating aorto-iliac thrombosis: A rare complication of COVID-19 pneumonia. ⁶²	Ikrou H...Nassik H	36415471	2023
4	Impella Versus Extracorporeal Membranous Oxygenation (ECMO) for Cardiogenic Shock: A Systematic Review and Meta-analysis. ⁶²	Ahmad S...Goldsweig AM	36174742	2023
5	Development of a Non-Invasive Local Heating Load Test to Detect Severe Limb Ischemia Within 200 seconds. ⁶²	Katsui S...Kudo T	35968758	2023
6	New experimental model of hind limb ischemia in pot-bellied pigs. ⁶²	Samatoshenkov I...Heldwein MB	36089076	2023
7	Frailty predicts poor longer-term outcomes in patients following lower limb open surgical revascularization. ⁶²	Kalyanasundaram A...Coughlin PA	36168946	2022
8	Temporal analysis of skeletal muscle remodeling post hindlimb ischemia reveals intricate autophagy regulation. ⁶²	Scalabrin M...Bowen TS	36252128	2022
9	Unexpected arterial thrombosis and acute limb ischemia in COVID-19 patients. Results from the Ibero-Latin American acute arterial thrombosis registry in COVID-19: (ARTICO-19). ⁶²	Gonzalez-Urquijo M...ARTICO-19 Research Collaborative Group	34866506	2022
10	Comparative study of mouse adipose- and bone marrow mesenchymal stem cells in diabetic model with critical limb ischemia. ⁶²	Asadi-Yousefabad SL...Razban V	35590084	2022
11	Arterial thoracic outlet syndrome: a 30-year experience in a high-volume referral center. ⁶²	Davidovic LB...Matejevic D	36106396	2022
12	Rivaroxaban in Patients with Symptomatic Peripheral Artery Disease after Lower Extremity Bypass Surgery with Venous and Prosthetic Conduits. ⁶²	Govsyeyev N...Bonaca MP	36470531	2022
13	Endothelium dysfunction in hind limb arteries of male Zucker Diabetic-Sprague Dawley rats. ⁶²	Wang AN...McGuire JJ	36279920	2022
14	Twelve-Month Outcomes From the Japanese Post-Market Surveillance Study of the Viabahn Endoprosthesis as Treatment for Symptomatic Peripheral Arterial Disease in the Superficial Femoral Arteries. ⁶²	Iida O...Ichihashi S	34905961	2022
15	Prevalence of frailty in patients with lower extremity peripheral arterial disease: A systematic review and meta-analysis. ⁶²	Wang Y...Yang Y	36216291	2022
16	Resuscitating the resuscitation: A single-centre experience on extracorporeal cardiopulmonary resuscitation. ⁶²	Ozturk Z...Bayrakci B	36453833	2022
17	Novel approaches to antiplatelet therapy. ⁶²	Gresele P...Momi S	36243098	2022
18	Cannulation-related adverse events of peripheral veno-arterial extracorporeal membrane oxygenation support in heart transplantation: Axillary versus femoral artery cannulation. ⁶²	Ohira S...Kai M	36468757	2022
19	A remarkably rare case of Adventitial Cystic Disease of the Popliteal Artery in a 51-year-old Middle Eastern female - A Case Report. ⁶²	Hariri O...Nahas MA	36462233	2022
20	Immune checkpoint inhibitors and the risk of major atherosclerotic cardiovascular events in patients with high-risk or advanced melanoma: a retrospective cohort study. ⁶²	Wang C...Mar V	36461057	2022
21	Buttock Ischemia in Venoarterial Extracorporeal Membrane Oxygenation: A Case Series. ⁶²	Wong ASK...Sin SWC	35275880	2022
22	Prolonged lower extremity endovascular procedures for patients with claudication increase risk of adverse outcomes. ⁶²	Ostapenko A...Dietzek AM	35840074	2022
23	Association of Clinical Setting With Sociodemographics and Outcomes Following Endovascular Femoropopliteal Artery Revascularization in the United States. ⁶²	Raja A...Secemsky EA	36472193	2022
24	Saphenous and sciatic nerve block to treat acute lower limb ischemic pain in the emergency department. ⁶²	Ransford G...Byars D	35460505	2022
25	Long-term Follow-up of a Randomized Clinical Trial Comparing Endovascular Revascularization Plus Supervised Exercise With Supervised Exercise Only for Intermittent Claudication. ⁶²	Klaphake S...Hunink MGM	33378308	2022
26	2D perfusion angiography: an alternative method to evaluate endovascular intervention for acute lower limb ischemia. ⁶²	Li W...Li C	36463099	2022
27	Marrow changes and reduced proliferative capacity of mesenchymal stromal cells from patients with "no-option" critical limb ischemia; observations on feasibility of the autologous approach from a clinical trial. ⁶²	Mohamed SA...Howard L	35999133	2022
28	Porous scaffold for mesenchymal cell encapsulation and exosome-based therapy of ischemic diseases. ⁶²	Czosseck A...Lundy DJ	36370875	2022
29	Cryptogenic acute lower extremities and multiorgan ischemia in an 8-year-old girl. ⁶²	Setia O...Ochoa Chaar CI	36248384	2022
30	Ten-year experience of infrainguinal bypass with endoscopic vein harvest. ⁶²	Khorfan R...Aziz A	36446034	2022
31	Venoarterial extracorporeal membrane oxygenation (VA-ECMO) with vs without left ventricular unloading by Impella: a systematic review and meta-analysis. ⁶²	Cappannoli L...D'Amario D	36370449	2022
32	Access site complications of postcardiotomy extracorporeal life support. ⁶²	Schaefer AK...Wiedemann D	34949456	2022
33	Midterm Outcomes of Endovascular Versus Open Surgical Repair of Intact Descending Thoracic Aneurysms in Patients with Connective Tissue Disorders. ⁶²	Muncan B...Price LZ	35460854	2022
34	Denser fibrin clot networks in patients at high risk of recurrent arterial thromboembolism following acute limb ischemia of unknown cause. ⁶²	Nowakowski T...Undas A	36264044	2022
35	Comparisons of outcomes of open surgery versus endovascular intervention for thrombotic popliteal artery aneurysm with acute lower limb ischemia: a systematic review. ⁶²	Xiao X...Wang S	36401240	2022
36	AhR regulates VEGF expression by promoting STAT1 transcriptional activity, thereby affecting endothelial angiogenesis in acute limb ischemia. ⁶²	Ma J...Liang K	36347318	2022
37	Adipose-derived stem cell-secreted exosomes enhance angiogenesis by promoting macrophage M2 polarization in type 2 diabetic mice with limb ischemia via the JAK/STAT6 pathway. ⁶²	Wang X...Gao Y	36406687	2022
38	Large thrombus in non-atherosclerotic thoracic ascending aorta as the source of acute upper limb ischemia in a young cocaine user. ⁶²	Lojo-Lendoiro S...Mosquera-Barreiro M	36441134	2022
39	Peripherally inserted concomitant surgical right and left ventricular support, the Propella, is associated with low rates of limb ischemia, with mortality comparable with peripheral venoarterial extracorporeal membrane oxygenation. ⁶²	Walsh RW...Rossi PJ	36435648	2022
40	Characteristics and Outcomes of Patients Transferred for Treatment of Acute Limb Ischemia. ⁶²	Endicott KM...Nagarsheth K	35803462	2022
41	Therapeutic angiogenesis for patients with no-option critical limb ischemia by adipose-derived regenerative cells: TACT-ADRC multicenter trial. ⁶²	Shimizu Y...TACT-ADRC multicenter trial Group	35802311	2022
42	Radio-iodination and biological evaluation of pentoxifylline as a novel probe for diagnosis of intermittent claudication. ⁶²	Motaleb MA...Aboumanei MH	36037727	2022
43	Catastrophic Vascular Injury After Total Knee Arthroplasty. ⁶²	Petis SM...Abdel MP	36098573	2022
44	Acute Limb Arterial Ischemia Following Iliac Vein Stenting in the Setting of a Frozen Pelvis. ⁶²	Trinidad B...Leon LR	35921088	2022
45	Effects of sensory nerve blockade on cutaneous microvascular responses to ischemia-reperfusion injury. ⁶²	McGarr GW...Cheung SS	35970407	2022
46	Randomized Trials of Percutaneous Microaxial Flow Pump Devices: JACC State-of-the-Art Review. ⁶²	Pahuja M...Waksman R	36396205	2022
47	Differences in major limb outcomes by indication for lower extremity endovascular revascularization in patients receiving hemodialysis. ⁶²	Iwai T...Higashitani M	36322238	2022
48	CircANKRD12 Is Induced in Endothelial Cell Response to Oxidative Stress. ⁶²	Voellenkle C...Martelli F	36428974	2022
49	Chronic Anti-Coagulation Therapy Reduced Mortality In Patients With High Cardiovascular Risk Early In COVID-19 Pandemic. ⁶²	Zaghloul MS...Zayed MA	36415466	2022
50	COVID-19 related peripheral arterial thrombotic events in intensive care unit and non-intensive care unit patients: A retrospective case series. ⁶²	Nana P...Matsagkas M	36395575	2022

Sources

Genes for Limb Ischemia

Genes related to Limb Ischemia (0 elite genes):

(show all 33)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	MIR126	MicroRNA 126	RNA Gene	9.57	DISEASES inferred ¹⁴ ¹⁴
2	MIR21	MicroRNA 21	RNA Gene	8.07	DISEASES inferred ¹⁴ ¹⁴
3	MIR17	MicroRNA 17	RNA Gene	7.71	DISEASES inferred ¹⁴ ¹⁴
4	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	7.56	DISEASES inferred ¹⁴
5	PECAM1	Platelet And Endothelial Cell Adhesion Molecule 1	Protein Coding	7.29	DISEASES inferred ¹⁴
6	CD34	CD34 Molecule	Protein Coding	7.21	DISEASES inferred ¹⁴
7	FGF2	Fibroblast Growth Factor 2	Protein Coding	7.1	DISEASES inferred ¹⁴
8	NOS3	Nitric Oxide Synthase 3	Protein Coding	6.82	DISEASES inferred ¹⁴
9	KDR	Kinase Insert Domain Receptor	Protein Coding	6.8	DISEASES inferred ¹⁴
10	HGF	Hepatocyte Growth Factor	Protein Coding	6.79	DISEASES inferred ¹⁴
11	CXCL12	C-X-C Motif Chemokine Ligand 12	Protein Coding	6.7	DISEASES inferred ¹⁴
12	ANGPT1	Angiopoietin 1	Protein Coding	6.67	DISEASES inferred ¹⁴
13	MIR10A	MicroRNA 10a	RNA Gene	6.63	DISEASES inferred ¹⁴ ¹⁴
14	VWF	Von Willebrand Factor	Protein Coding	6.59	DISEASES inferred ¹⁴
15	ENG	Endoglin	Protein Coding	6.56	DISEASES inferred ¹⁴
16	HIF1A	Hypoxia Inducible Factor 1 Subunit Alpha	Protein Coding	6.53	DISEASES inferred ¹⁴
17	CRP	C-Reactive Protein	Protein Coding	6.53	DISEASES inferred ¹⁴
18	F3	Coagulation Factor III, Tissue Factor	Protein Coding	6.51	DISEASES inferred ¹⁴
19	TEK	TEK Receptor Tyrosine Kinase	Protein Coding	6.45	DISEASES inferred ¹⁴
20	IL6	Interleukin 6	Protein Coding	6.44	DISEASES inferred ¹⁴
21	PTPRC	Protein Tyrosine Phosphatase Receptor Type C	Protein Coding	6.4	DISEASES inferred ¹⁴
22	PROM1	Prominin 1	Protein Coding	6.36	DISEASES inferred ¹⁴
23	PLG	Plasminogen	Protein Coding	6.35	DISEASES inferred ¹⁴
24	THY1	Thy-1 Cell Surface Antigen	Protein Coding	6.34	DISEASES inferred ¹⁴
25	CDH5	Cadherin 5	Protein Coding	6.33	DISEASES inferred ¹⁴
26	CSF3	Colony Stimulating Factor 3	Protein Coding	6.26	DISEASES inferred ¹⁴
27	ACE	Angiotensin I Converting Enzyme	Protein Coding	6.25	DISEASES inferred ¹⁴
28	NT5E	5'-Nucleotidase Ecto	Protein Coding	6.21	DISEASES inferred ¹⁴
29	ALB	Albumin	Protein Coding	6.2	DISEASES inferred ¹⁴
30	CXCR4	C-X-C Motif Chemokine Receptor 4	Protein Coding	6.19	DISEASES inferred ¹⁴
31	MIR200C	MicroRNA 200c	RNA Gene	6.11	DISEASES inferred ¹⁴ ¹⁴
32	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	6.11	DISEASES inferred ¹⁴
33	SERPINC1	Serpin Family C Member 1	Protein Coding	6.1	DISEASES inferred ¹⁴

Sources

Variations for Limb Ischemia

Sources

Expression for Limb Ischemia

Search GEO for disease gene expression data for Limb Ischemia.

Sources

Pathways for Limb Ischemia

Pathways related to Limb Ischemia according to GeneCards Suite gene sharing:

(show top 50) (show all 53)

#	Super pathways	Score	Top Affiliating Genes
1	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.81	VEGFA TEK KDR IL6 HIF1A HGF
2	Signal Transduction ⁶⁶	13.67	ANGPT1 CXCL12 F3 FGF2 HGF HIF1A
3	MIF Mediated Glucocorticoid Regulation ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ Overview of proinflammatory and profibrotic mediators ⁷⁴ PEDF Induced Signaling ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.62	VEGFA TEK NOS3 KDR IL6 HGF
4	Activation of cAMP-Dependent PKA ⁶⁴ Show member pathways Activation of PKA through GPCR ⁶⁴ cAMP Pathway ⁶⁴ PKA Signaling ⁶⁴	13.55	CRP CXCL12 FGF2 HGF IL6 KDR
5	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.53	VEGFA TEK KDR IL6 HGF FGF2
6	RAF/MAP kinase cascade ⁶⁶ Show member pathways Diseases of signal transduction by growth factor receptors and second messengers ⁶⁶ MAPK family signaling cascades ⁶⁶ MAPK1/MAPK3 signaling ⁶⁶	13.37	VWF TEK KDR IL6 HGF FGF2
7	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.35	ANGPT1 CXCL12 FGF2 HGF IL6 KDR
8	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.28	TEK KDR IL6 HGF FGF2 CXCL12
9	Response to elevated platelet cytosolic Ca2+ ⁶⁶ Show member pathways Disinhibition of SNARE formation ⁶⁶ Hemostasis ⁶⁶ Platelet activation, signaling and aggregation ⁶⁶ Platelet degranulation ⁶⁶	13.23	VWF VEGFA TEK PECAM1 NOS3 HGF
10	Nanog in Mammalian ESC Pluripotency ⁶⁴ Show member pathways 14-3-3 Induced Intracellular Signaling ⁶⁴ eNOS Signaling ⁶⁴ GSK3 Signaling ⁶⁴	13.21	CXCL12 FGF2 HGF IL6 KDR NOS3
11	p70S6K Signaling ⁶⁴ Show member pathways mTOR Pathway ⁶⁴ Renin-Angiotensin Pathway ⁶⁴	13.04	KDR IL6 HIF1A HGF FGF2 CXCL12
12	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	12.83	ANGPT1 FGF2 HGF HIF1A IL6 KDR
13	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.69	VEGFA NOS3 KDR HIF1A HGF FGF2
14	NF-KappaB Family Pathway ⁶⁴ Show member pathways NF-KappaB (p50-p65) Pathway ⁶⁴	12.68	KDR IL6 HGF FGF2 CXCL12
15	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.55	TEK NOS3 IL6 FGF2 ANGPT1
16	Malignant pleural mesothelioma ⁷⁴	12.52	VEGFA TEK KDR IL6 HIF1A HGF
17	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	12.35	TEK KDR IL6 HGF FGF2 CXCL12
18	Focal adhesion ⁷⁴	12.27	HGF KDR VEGFA VWF
19	VEGF Signaling Pathway ⁶⁰ ⁶⁷ Show member pathways Nanoparticle-mediated activation of receptor signaling ⁷⁴ TGF-beta Signaling ⁶⁷	12.18	VEGFA NOS3 KDR FGF2
20	Embryonic and Induced Pluripotent Stem Cells and Lineage-specific Markers ⁶⁵	12.02	VEGFA KDR IL6 HGF FGF2
21	Interleukin-4 and Interleukin-13 signaling ⁶⁶	11.89	VEGFA IL6 HIF1A HGF FGF2
22	Mesenchymal Stem Cells and Lineage-specific Markers ⁶⁵	11.85	IL6 FGF2 ENG CD34
23	Clear cell renal cell carcinoma pathways ⁷⁴	11.82	VEGFA KDR HIF1A
24	Network map of SARS-CoV-2 signaling pathway ⁷⁴ Show member pathways Pathogenesis of SARS-CoV-2 mediated by nsp9-nsp10 complex ⁷⁴	11.77	IL6 HIF1A CRP
25	Extrafollicular B cell activation by SARS-CoV-2 ⁷⁴	11.73	IL6 CXCL12 CRP
26	Burn wound healing ⁷⁴	11.68	VEGFA PECAM1 IL6 HGF CXCL12
27	Signaling events mediated by VEGFR1 and VEGFR2 ⁶¹	11.66	VEGFA NOS3 KDR
28	Lung fibrosis ⁷⁴	11.66	IL6 HGF FGF2
29	HIF-1-alpha transcription factor network ⁶¹	11.66	VEGFA HIF1A ENG CXCL12
30	miRNAs involvement in the immune response in sepsis ⁷⁴	11.65	MIR21 MIR126 IL6
31	Integrins in angiogenesis ⁶¹	11.6	VEGFA KDR FGF2
32	Hepatitis C and hepatocellular carcinoma ⁷⁴	11.57	VEGFA IL6 HIF1A
33	HIF1Alpha Pathway ⁶⁴	11.56	VEGFA NOS3 HIF1A
34	NRP1-triggered signaling pathways in pancreatic cancer ⁷⁴	11.55	VEGFA PECAM1 KDR HGF
35	Cell adhesion_Plasmin signaling ²²	11.51	VEGFA KDR FGF2
36	Pluripotent stem cell differentiation pathway ⁷⁴	11.49	VEGFA IL6 HGF FGF2
37	Signaling events mediated by TCPTP ⁶¹ Show member pathways MET activates PI3K/AKT signaling ⁶⁶	11.47	VEGFA KDR HGF
38	Genes controlling nephrogenesis ⁷⁴	11.45	VEGFA KDR CXCL12
39	Vemurafenib Pathway, Pharmacodynamics ⁶⁰	11.44	VEGFA KDR FGF2
40	Beta3 integrin cell surface interactions ⁶¹	11.38	VEGFA PECAM1 KDR
41	Photodynamic therapy-induced HIF-1 survival signaling ⁷⁴	11.36	VEGFA HIF1A ANGPT1
42	Neovascularisation processes ⁷⁴	11.27	KDR HIF1A CXCL12 ANGPT1
43	Angiogenesis (CST) ³	11.27	VWF TEK PECAM1 NOS3 KDR HIF1A
44	Development_Leptin signaling via JAK/STAT and MAPK cascades ²² Show member pathways phospho-PLA2 pathway ⁶⁶	11.25	VEGFA HIF1A CRP
45	VEGFR1 specific signals ⁶¹	11.17	VEGFA NOS3 HIF1A
46	SHP2 signaling ⁶¹	11.17	VEGFA TEK NOS3 KDR IL6 ANGPT1
47	G-protein signaling_Rap2B regulation pathway ²²	10.98	TEK KDR IL6 HGF FGF2 CXCL12
48	Angiogenesis (WikiPathways) ⁷⁴	10.83	TEK NOS3 KDR HIF1A FGF2
49	Aspirin and miRNAs ⁷⁴	10.71	VEGFA NOS3
50	MicroRNA for targeting cancer growth and vascularization in glioblastoma ⁷⁴ Show member pathways Oncostatin M signaling pathway ⁷⁴	10.66	VEGFA HIF1A

Sources

GO Terms for Limb Ischemia

Cellular components related to Limb Ischemia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular region	GO:0005576	10.02	VWF VEGFA TEK KDR IL6 HGF
2	extracellular space	GO:0005615	9.72	ANGPT1 CRP CXCL12 ENG F3 FGF2

Biological processes related to Limb Ischemia according to GeneCards Suite gene sharing:

(show all 48)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of apoptotic process	GO:0043066	10.44	ANGPT1 HGF HIF1A IL6 KDR MIR21
2	negative regulation of gene expression	GO:0010629	10.37	VEGFA MIR21 MIR17 KDR HIF1A FGF2
3	angiogenesis	GO:0001525	10.34	VEGFA TEK NOS3 KDR HIF1A FGF2
4	positive regulation of cell migration	GO:0030335	10.32	CXCL12 F3 HGF KDR MIR10A MIR21
5	positive regulation of protein phosphorylation	GO:0001934	10.3	ANGPT1 ENG FGF2 HGF KDR MIR21
6	positive regulation of gene expression	GO:0010628	10.3	ANGPT1 CD34 CRP ENG F3 FGF2
7	positive regulation of ERK1 and ERK2 cascade	GO:0070374	10.29	VEGFA TEK MIR21 MIR126 KDR FGF2
8	positive regulation of MAPK cascade	GO:0043410	10.29	FGF2 HGF IL6 KDR MIR126 TEK
9	positive regulation of peptidyl-tyrosine phosphorylation	GO:0050731	10.28	ANGPT1 HGF IL6 PECAM1 VEGFA
10	positive regulation of endothelial cell proliferation	GO:0001938	10.25	VEGFA TEK KDR HIF1A FGF2 F3
11	positive chemotaxis	GO:0050918	10.21	VEGFA HGF FGF2 ANGPT1
12	lung development	GO:0030324	10.19	FGF2 KDR NOS3 VEGFA
13	positive regulation of interleukin-10 production	GO:0032733	10.18	IL6 HGF CD34
14	positive regulation of osteoblast differentiation	GO:0045669	10.17	MIR21 IL6 HGF FGF2
15	positive regulation of endothelial cell migration	GO:0010595	10.17	ANGPT1 FGF2 KDR MIR21 TEK VEGFA
16	cellular response to hypoxia	GO:0071456	10.16	VEGFA MIR17 MIR126 HIF1A
17	branching involved in blood vessel morphogenesis	GO:0001569	10.14	VEGFA KDR ENG
18	positive regulation of neuroblast proliferation	GO:0002052	10.13	VEGFA HIF1A FGF2
19	positive regulation of protein kinase B signaling	GO:0051897	10.13	VEGFA TEK MIR21 MIR126 FGF2 F3
20	positive regulation of focal adhesion assembly	GO:0051894	10.12	VEGFA TEK KDR
21	endothelial cell proliferation	GO:0001935	10.12	TEK FGF2 CD34
22	sprouting angiogenesis	GO:0002040	10.12	ANGPT1 ENG TEK VEGFA
23	negative regulation of endothelial cell apoptotic process	GO:2000352	10.11	ANGPT1 KDR MIR126 TEK
24	cell migration involved in sprouting angiogenesis	GO:0002042	10.1	VEGFA KDR FGF2
25	positive regulation of positive chemotaxis	GO:0050927	10.09	F3 KDR VEGFA
26	vascular wound healing	GO:0061042	10.08	VEGFA KDR CD34
27	positive regulation of cell migration involved in sprouting angiogenesis	GO:0090050	10.06	VEGFA MIR126 MIR10A KDR FGF2
28	positive regulation of sprouting angiogenesis	GO:1903672	10.04	VEGFA MIR126 FGF2
29	positive regulation of cytokine production involved in inflammatory response	GO:1900017	10.03	MIR21 MIR17 IL6 HIF1A
30	positive regulation of DNA biosynthetic process	GO:2000573	10.02	VEGFA HGF FGF2
31	positive regulation of vascular associated smooth muscle cell proliferation	GO:1904707	10	MIR21 MIR17 FGF2
32	vascular endothelial growth factor receptor-2 signaling pathway	GO:0036324	10	KDR VEGFA
33	positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway	GO:0038033	9.99	KDR VEGFA
34	positive regulation of transcription from RNA polymerase II promoter in response to hypoxia	GO:0061419	9.99	HIF1A VEGFA
35	Tie signaling pathway	GO:0048014	9.98	ANGPT1 TEK
36	glomerular endothelium development	GO:0072011	9.97	CD34 PECAM1
37	glomerulus vasculature development	GO:0072012	9.97	ANGPT1 TEK
38	positive regulation of blood vessel endothelial cell migration	GO:0043536	9.97	ANGPT1 FGF2 HIF1A KDR MIR126 NOS3
39	positive regulation of vascular endothelial cell proliferation	GO:1905564	9.93	FGF2 MIR126 MIR21
40	positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis	GO:1903589	9.93	MIR10A MIR126 MIR21 VEGFA
41	negative regulation of interleukin-1-mediated signaling pathway	GO:2000660	9.88	MIR21 IL6
42	positive regulation of epithelial tube formation	GO:1905278	9.86	VEGFA FGF2
43	negative regulation of hydrogen peroxide-mediated programmed cell death	GO:1901299	9.84	HGF MIR21
44	positive regulation of vascular associated smooth muscle cell differentiation	GO:1905065	9.83	MIR21 ENG
45	positive regulation of phosphatidylinositol 3-kinase signaling	GO:0014068	9.77	VEGFA TEK MIR21 MIR126 KDR HGF
46	negative regulation of vascular associated smooth muscle cell apoptotic process	GO:1905460	9.69	MIR17 MIR21
47	positive regulation of metalloendopeptidase activity	GO:1904685	9.68	MIR21 MIR17
48	positive regulation of angiogenesis	GO:0045766	9.66	CD34 ENG F3 FGF2 HGF HIF1A

Molecular functions related to Limb Ischemia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mRNA base-pairing translational repressor activity	GO:1903231	9.46	MIR21 MIR17 MIR126 MIR10A
2	chemoattractant activity	GO:0042056	9.43	VEGFA HGF FGF2
3	growth factor activity	GO:0008083	9.32	VEGFA IL6 HGF FGF2 CXCL12